Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Study to Assess the Effect of Naltrexone Hydrochloride Extended Release (ER) and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on the Occurrence of Major Adverse Cardiovascular Events

NCT06098079 is registered in ClinicalTrials.gov with Currax Pharmaceuticals as lead sponsor.

NCT NCT06098079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06098079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Study to Assess the Effect of Naltrexone Hydrochloride Extended Release (ER) and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on the Occurrence of Major Adverse Cardiovascular Events
Lead sponsor
Currax Pharmaceuticals
Phase
Phase 4
Overall status
Active, not recruiting
Start date
January 3, 2024
Completion date
July 31, 2029
Enrollment
8,600 (estimated)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

obesity